BioCentury
ARTICLE | Company News

Perrigo to separate its generics business

August 17, 2018 5:26 PM UTC

Perrigo Co. plc (NYSE:PRGO; Tel Aviv:PRGO) said it plans to separate its prescription generics business to focus on its consumer healthcare products. The company expects the transaction -- which could include a separation to shareholders, sale or merger -- to complete in 2H19.

Perrigo plans to provide an update on its plans for the prescription business, which comprises a portfolio of topical generic medicines, on a conference call Sept. 25...

BCIQ Company Profiles

Merck & Co. Inc.

Perrigo Co. plc